News - Anti-Arthritics/Rheumatics


Popular Filters

101 to 125 of 297 results

Third milestone for Neovacs in the Tracker program for rheumatoid arthritis


French biotech firm Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment…


Novartis' Ilaris gets new indication of childhood arthritis from US FDA


Swiss pharmaceutical major Novartis (NIVN: VX) said this morning (May 10) that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsNorth AmericaPharmaceuticalRare diseasesRegulation

Concert Pharma in $300 million-plus deal with Celgene


Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Merck & Co wins Fosamax federal bellwether trial over atypical femur fracture claims


A US has jury found in favor of pharma giant Merck & Co (NYSE: MRK) in the Glynn versus Merck case in…

Anti-Arthritics/RheumaticsFosamaxLegalMerck & CoNorth AmericaPharmaceutical

EMA committee gives thumbs down for Pfizer's Xeljanz for RA


Shares of Pfizer (NYSE: PFE) fell 2.4% to $29.53 in extended New York trading yesterday, after the pharma…


UK's NICE gives final guidance on Esbriet, Orencia and Xolair


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

New Zealand considers listing of Neulastim and Actemra


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list pegfilgrastim…


Thought leader views on new osteoporosis and osteopenia treatments


US and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is…

AMG-785AmgenAnti-Arthritics/RheumaticsBiotechnologyCDP-7851Eli LillyEuropeHealthcareMarkets & MarketingMerck & CoNorth AmericaodanacatibPharmaceuticalteriparatideUCB

Mixed top-line results for AstraZeneca's RA drug candidate fostamatinib


Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning reported top-line results from the Phase…


AbbVie's Humira cleared in EU for polyarticular juvenile idiopathic arthritis


The European Commission has approved an extension of the European Union marketing authorization for US…


Specialty drug costs account for over 50% of the total cost of care for RA and hepatitis C patients in USA


According to two new studies by Prime Therapeutics, a leading US pharmacy benefit manager, rheumatoid…

Anti-Arthritics/RheumaticsAnti-viralsBiotechnologyFinancialHealthcareNorth AmericaPharmaceutical

BioTrends views Xeljanz and Zytiga prescribing in USA


After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

NPS Pharma regains rights to Revestive and Preotact from Takeda


USA-based NPS Pharmaceuticals (Nasdaq: NPSP) has re-gained the full worldwide rights from partner Takeda…

Anti-Arthritics/RheumaticsGastro-intestinalsGattexLicensingNatparaNPS PharmaceuticalsPharmaceuticalPreotactRevestiveTakeda Pharmaceuticals

Roche's RoActemra shows superiority to Humira in rheumatoid arthritis


Over 50% of rheumatoid arthritis patients can achieve low disease activity or remission with Swiss drug…


Merck Serono collaborates with Nordic Bioscience for sprifermin in osteoarthritis


German drug and chemical major Merck KGaA (MRK: DE) says its Merck Serono division has entered into a…

Anti-Arthritics/RheumaticsMerck KGaAMerck SeronoNordic BiosciencePharmaceuticalResearchsprifermin

Switch to anabolics driving osteoporosis market growth


A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency


Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

NICE green light for earlier use of Bristol-Myers' Orencia


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) now recommends…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalRegulation

USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015


Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

101 to 125 of 297 results

Company Spotlight



Back to top